Xavier Lucas1, Inge Van Molle2, Alessio Ciulli1. 1. Division of Biological Chemistry and Drug Discovery, James Black Centre, School of Life Sciences , University of Dundee , Dow Street , Dundee , DD1 5EH , United Kingdom. 2. Department of Chemistry , University of Cambridge , Cambridge CB2 1EW , United Kingdom.
Abstract
Beyond the targeting of E3 ubiquitin ligases to inhibit protein homeostasis, E3 ligase binders can be repurposed as targeted protein degraders (PROTACs or molecular glues). We sought to identify new binders of the VHL E3 ligase by biophysical fragment-based screening followed by X-ray crystallographic soaking. We identified fragments binding at the ElonginC:Cullin2 interface and a new cryptic pocket in VHL, along with other potential ligandable sites predicted computationally and found to bind solvent molecules in crystal structures. The elucidated interactions provide starting points for future ligand development.
Beyond the targeting of E3 ubiquitin ligases to inhibit protein homeostasis, E3 ligase binders can be repurposed as targeted protein degraders (PROTACs or molecular glues). We sought to identify new binders of the VHL E3 ligase by biophysical fragment-based screening followed by X-ray crystallographic soaking. We identified fragments binding at the ElonginC:Cullin2 interface and a new cryptic pocket in VHL, along with other potential ligandable sites predicted computationally and found to bind solvent molecules in crystal structures. The elucidated interactions provide starting points for future ligand development.
E3 ubiquitin ligases
covalently modify protein substrates by catalyzing
ubiquitin transfer from an E2-conjugating enzyme to substrate proteins,
thereby marking substrates for proteasomal degradation.[1] The largest subfamily of E3 ubiquitin ligases
are Cullin (Cul)-RING ligases (CRLs), which consist of large modular
assemblies comprising a RING domain, a scaffolding Cul subunit, one
or more adaptor proteins, and a substrate-recognition subunit that
binds to specific protein motifs termed degrons.[2,3] An
archetypical example is the von Hippel–Lindau protein (VHL),
which functions as the substrate-binding module of CRL2VHL, a CRL consisting of VHL, the adaptor proteins Elongin B (EloB)
and Elongin C (EloC), Cul2, and Rbx1. VHL features a hydroxyproline
(Hyp) recognition site that targets for degradation post-translationally
hydroxylated hypoxia-inducible factor (HIF)-1α subunits.[4,5] Crystal structures of VHL:EloC:EloB (VCB) in complex with Hyp-containing
HIF-1α peptides[6,7] provided the structural basis
of Hyp recognition by VCB[8] and inspired
the design of potent, cell-active Hyp-containing small-molecule inhibitors
of VHL.[9−12]Beyond VHL, the substrate-recognition subunit of only few
other
CRLs has been targeted using small molecules.[3] Notably, CRL binders can be converted into targeted protein degraders
by conjugating them to a ligand of a protein of interest.[13] These bivalent compounds, also termed proteolysis-targeting
chimeras (PROTACs), have been developed to induce cellular degradation
of a wide range of protein targets, including transcription factors,
epigenetic targets, and kinases.[14−17] We have recently presented the
first crystal structure of VCB in complex with a PROTAC and the target
protein, highlighting the importance of inducing stable and cooperative
protein–protein recognition around the target E3 ligase site.[18] Exploiting such ternary complex recognition,
we have also shown that E3 ligase binders can be turned into avid
dimerizers that can induce an E3 ligase to destroy itself.[19] Unlike conventional protein inhibitors, the
activity of PROTACs is not dependent upon the biological function
or perceived druggability of the attachment sites.[13,20] Therefore, ligandable pockets in E3 ubiquitin ligases aside from
the conventional degron-recognition pocket could potentially be exploited
to anchor PROTACs or as molecular glues.[3] So far, however, ligandable pockets in VCB apart from the HIF-recognition
site remain unknown.The successful small-molecule modulation
of the function of specific
protein classes historically deemed intractable has motivated a growing
interest in developing technologies to probe protein surfaces and
identify secondary binding sites.[21,22] In particular,
fragment screening by X-ray crystallography and NMR has seen widespread
application.[23−26] From a computational perspective, a variety of empirical-, grid-,
and force-field based methods have been developed.[27] Tools such as SiteMap[28] and
FTMap[29,30] are routinely used to predict and analyze
protein–ligand and protein–protein interfaces[31,32] as well as to study cryptic pockets.[33] Mixed-solvent molecular dynamics (MD) simulations enable solvent
mapping with protein flexibility and explicit water, albeit at a substantial
computational cost.[34] This method has also
been used to detect and study allosteric sites, cryptic pockets, and
hotspots of intermolecular interaction.[34−38]Herein we probe the surface of VCB to identify
binding sites by
fragment-based screening and computational pocket detection methods.
The screening hits were validated by X-ray crystallography, which
revealed two novel ligandable pockets: one involving the EloC:Cul
interface and the other involving a previously unknown cryptic pocket
in VHL. In addition, computational approaches located other potential
sites in VCB that bind solvent molecules in available crystallographic
data, suggesting that they could also be ligandable.
Results and Discussion
The biophysical cascade consisted of a primary screen of over 1200
rule of three-compliant fragments from the Maybridge library using
differential scanning fluorimetry (DSF) and of 144 fragments randomly
picked from the same library using one-dimensional 1H NMR
spectroscopy.[40] Screening hits were validated
by NMR spectroscopy and subsequent X-ray crystallography (Supporting
Information (SI), Figure S1).DSF
monitors the unfolding temperature of a protein using a fluorescent
dye that preferentially binds to unfolded proteins. We screened our
fragment library, assayed as singletons, against both VCB and VCB
preincubated with HIF-1α peptide (VCBH). We reasoned that this
approach could aid identification and direct discrimination between
binders of the HIF site and binders elsewhere in the complex. DSF
hits were defined as fragments resulting in an increase in melting
temperature (ΔTm = Tm,protein+fragment – Tm,protein) of either VCB or VCBH greater than 0.5 °C. In addition, five
fragments were considered hits due to their effect on the overall
melting properties of VCB. In total, 65 unique hits were identified
by DSF (5.2% overall hit rate). In parallel, the ligand-based NMR
screen was performed in cocktails of three fragments. We carried out
a series of one-dimensional 1H NMR spectroscopy binding
experiments: water ligand observed gradient spectroscopy (waterLOGSY),
saturation transfer difference (STD), and Carr–Purcell–Meiboom–Gill
(CPMG) relaxation-edited sequences.[41] In
these experiments, binding was assessed by comparing the proton signals
of the fragments in the presence and in the absence of VCB. Specific
binding to the VHL:HIF interface was probed by subsequently monitoring
displacement of the ligand signals using the HIF-1α peptides
10-mer DEALA-Hyp-YIPD or 19-mer DEALA-Hyp-YIPMDDDFQLRSF (Kd of 180 or 3 nM, respectively).[9,11] Fragments were considered hits in the NMR screen if they showed
binding in at least two of the three NMR experiments. This resulted
in 17 unique hits (11.8% overall hit rate).In total, 82 fragments
were selected as hits from these two primary
screens and subsequently validated by a second round of NMR experiments
(waterLOGSY, STD, and CPMG) as cocktails of two for the DSF hits and
as singletons for the NMR hits. This secondary screen validated 18
of the 82 hits identified in the primary screen (78.0% attrition rate).
Notably, all but one of the validated fragment hits were not displaced
by the HIF-1α peptide, suggesting that they may bind to other
sites on the VCB complex. To locate those potential new sites, we
soaked the 18 validated fragment hits in both VCB and VCBH crystals,
which have distinct crystal packing (P4122 for VCB and P43212 for
VCBH). This maximizes the likelihood of success in the crystallographic
fragment soaking by increasing the combined solvent-exposed surface
of the complex. The soaking experiment yielded three fragments binding
to sites in VCB other than the HIF-recognition site in VHL (Figure and SI, Figure S2 and Table S1), consistent with the
NMR data showing lack of competition by the HIF-1α peptide or
a Hyp-containing fragment binding weakly at the HIF site.[11] Fragments MB235 and MB1200 (PDB 6GMN and 6GMX, ΔTm = 0.7 and 1.2 °C against VCBH, respectively)
bind to a hydrophobic cleft in EloC that is only accessible in the
VCB crystals and occluded by crystal packing contacts in VCBH. The
newly identified binding site is defined by EloC residues E64, I65,
P66, E102, M105, A106, and F109. Both compounds share an aromatic
portion that forms hydrophobic contacts and a carbonyl group that
occupies the same position in the two crystal structures. The carbonyl
carbon of the fragments engages in a C=O···C=O
contact with the backbone carbonyl oxygen of E64EloC. Additionally,
we observe flexibility of the E64EloC side chain in the
cocrystal structures (Figure A,B). Superposition of EloC in complex with the fragments
and with Cul2 reveals that the fragments bind to the same cavity used
for recognition of L3Cul2 in the EloC:Cul2 interface (Figure D), which we have
recently probed using low-affinity peptides.[42] In contrast, MB756 binds to both VCB and VCBH crystals (PDB 6GMQ and 6GMR, respectively, ΔTm = 1.3 °C against VCB) in a previously
unknown cryptic pocket in VHL, located over 15 Å away from the
HIF-recognition site (Figure ). The pyrrole ring of MB756 is inserted in a pocket in VHL
formed by VHL residues L118, F119, R120, G127, L128, L129, E134, D197,
and L201. The pocket is accessible only after rearrangement of R120VHL, which acts as a gate amino acid to accommodate the fragment
(Figure E). Upon binding,
the pyrrole ring of the ligand engages in ion−π interactions
with R120VHL and E134VHL, and the phenolic hydroxyl
group protrudes away from the pocket to form hydrogen bonds to the
side chain of E160VHL and to a water molecule (Figure C). We used isothermal
titration calorimetry (ITC) to characterize the binding affinity of
the fragments to VCB (SI, Figure S3). Dissociation
constants of 5.0 and 6.7 mM were obtained for MB756 and MB1200, respectively,
resulting in a ligand efficiency (LE) of 0.24 and 0.25 kcal/mol·heavy
atom, respectively. We have previously shown that fragments in this
range of affinity and LE can be elaborated into high affinity binders.[43] Together, the results support specific binding
interactions and qualify these pockets as ligandable, at least to
weak-affinity fragments.
Figure 1
Fragment-based probing of the VHL:EloC:EloB
E3 ubiquitin ligase.
Chemical structure, F0 – Fc electron density omit map contoured at 3σ
level, and X-ray crystal structure of fragment (A) MB235 in complex
with VCB (PDB 6GMN), (B) MB1200 in complex with VCB (PDB 6GMX), and (C) MB756 in complex with VCBH
(PDB 6GMR).
Hydrogen bonds, ion−π interactions, and C=O···C=O
contacts are represented as yellow, cyan, and red dashed lines, respectively.
(D) Superposition of the crystal structure of VCB in complex with
MB235 and with Cul2 (PDB 4WQO),[39] colored deep teal and
yellow. L3Cul2 and fragments MB235 and MB1200 occupy the
same pocket in EloC. (E) Superposition of the crystal structure of
VCBH in complex with MB756 and of VCBH alone (PDB 4AJY),[11] colored deep teal. Note that formation of the cryptic pocket
requires rearrangement of the gate amino acid R120VHL.
Figure 2
Computational surface probing of the VHL:EloC:EloB
E3 ligase. Ligandable
pockets in VCB and sites predicted by SiteMap,[28] FTMap,[29,30] and mixed-solvent MD are highlighted.
Pockets identified by SiteMap and FTMap are colored according to druggability
classification. Consensus amino acids identified by mixed-solvent
MD are colored according to the percentage of frames in the mixed-solvent
MD simulation they are in contact with a buried probe. Predicted hotspots
1–3 are highlighted and labeled.
Fragment-based probing of the VHL:EloC:EloB
E3 ubiquitin ligase.
Chemical structure, F0 – Fc electron density omit map contoured at 3σ
level, and X-ray crystal structure of fragment (A) MB235 in complex
with VCB (PDB 6GMN), (B) MB1200 in complex with VCB (PDB 6GMX), and (C) MB756 in complex with VCBH
(PDB 6GMR).
Hydrogen bonds, ion−π interactions, and C=O···C=O
contacts are represented as yellow, cyan, and red dashed lines, respectively.
(D) Superposition of the crystal structure of VCB in complex with
MB235 and with Cul2 (PDB 4WQO),[39] colored deep teal and
yellow. L3Cul2 and fragments MB235 and MB1200 occupy the
same pocket in EloC. (E) Superposition of the crystal structure of
VCBH in complex with MB756 and of VCBH alone (PDB 4AJY),[11] colored deep teal. Note that formation of the cryptic pocket
requires rearrangement of the gate amino acid R120VHL.Computational surface probing of the VHL:EloC:EloB
E3 ligase. Ligandable
pockets in VCB and sites predicted by SiteMap,[28] FTMap,[29,30] and mixed-solvent MD are highlighted.
Pockets identified by SiteMap and FTMap are colored according to druggability
classification. Consensus amino acids identified by mixed-solvent
MD are colored according to the percentage of frames in the mixed-solvent
MD simulation they are in contact with a buried probe. Predicted hotspots
1–3 are highlighted and labeled.The newly discovered pockets in VCB are of substantial interest
in several research areas. First, we prove that the Cul interface
of EloC is ligandable and provide the first ligand-bound structures
of EloC. Second, the cryptic pocket in VHL involves the most frequently
occurring mutation in Chuvash polycythemia, R200W, which prevents
degradation of phosphorylated tyrosine-protein kinase JAK2 through
the proteasome.[44,45] Additionally, MB756 also contacts
the conserved P154VHL, which has been proposed to play
an important role in substrate poly ubiquitylation by CRLs.[46] Thus, elaborated higher-affinity binders could
serve as chemical biology tools to study E3 ligase activity and the
Chuvash disease at the molecular level. Notably, optimized compounds
binding to the new sites could also be converted into targeted protein
degraders, i.e., PROTACs.[13] The presence
of several ligandable pockets in VCB additionally sets an ideal, yet
challenging, scenario to explore these and other binding sites using
computational pocket detection methods. Thus, we next subjected VCB
to a surface probing campaign using SiteMap,[28] FTMap,[29,30] and mixed-solvent MD.[34]In the case of SiteMap and FTMap, we processed the
whole VCB complex
using standard parameters. For the mixed-solvent MD, we first selected
15 fragment-size molecules with varied physicochemical properties,
chemotypes, and molecular sizes as probes. We reasoned that exploration
of protein surfaces beyond druggability considerations requires thoughtful
yet bold probe selection. With this in mind, apart from traditional
probes typically used in solvent mapping, such as benzene and isobutanol,
we also considered biomimetics of peptidic bonds, a zwitterionic species,
a capped alanine, a biaryl, a fluorinated probe, and a sulfonamide
(SI, Figure S4 and Table S2). Each probe
was used to cosolvate VCB, and the whole system was then subjected
to MD simulations. Potential binding sites were identified by recording
consensus amino acids surrounding probes buried in the protein surface
during the simulations.Ligandable sites in VCB and those predicted
computationally are
highlighted in Figure . The three pockets validated experimentally provided a suitable
opportunity to benchmark the computational results. SiteMap and FTMap
were very successful in locating precisely the binding site of MB235
and MB1200, and the MD approach suggested the importance of surrounding
amino acids M105EloC and D179VHL in noncovalent
recognition (SI, Figures S8 and S9). Consistent
with these predictions, an M105AEloC mutant resulted in
a 35-fold decrease in binding affinity toward Cul2 compared to wild-type
EloC,[48] and a K4ACul2 mutant
peptide, which would prevent a salt bridge between K4Cul2 and D179VHL, exhibited no binding to VCB.[42] The HIF-recognition site in VHL was properly
detected by the mixed-solvent MD method. However, FTMap failed to
locate it and SiteMap perceived it as undruggable, consistent with
the observation that only one fragment targeting the HIF site emerged
from our biophysical screen (SI, Figure S1) and with the challenges in detecting binding of fragments resulting
from deconstructing ligands targeting this interface.[43] The methods also predicted a potentially druggable large
spot surrounding the cryptic pocket in VHL, suggesting that there
is promise in developing MB756 into a small-molecule binder by engaging
in farther favorable contacts (SI, Figure S10). Because mixed-solvent MD can reveal cryptic pockets,[36,38] we next investigated whether the simulations captured formation
of the MB756 cavity in VHL. Indeed, cosolvation of VCB with dioxopiperazine
induced opening of the pocket by triggering the required rearrangement
of R120VHL (Figure A,B). However, the probes did not occupy the cavity during
the simulations, presumably because of its hydrophobic nature (Figure C).
Figure 3
Structural analysis of
VHL:EloC:EloB E3 ubiquitin ligase sites.
Surface representation of the cryptic pocket in VHL in (A) the VCBH:MB756
cocrystal structure (PDB 6GMR) and in (B) a frame extracted from the MD trajectory
of VCB cosolvated with dioxopiperazine. Cul site in EloC upon superposition
of VCB:Cul2 (PDB 4WQO),[39] shown fogged, with (C) VCBH (PDB 4AJY)[11] and with (D) Gustavus:EloCB (PDB 2FNJ).[47] Crystal structure of VCB with (E) glycerol in hotspot 1
(PDB 4AJY) and
(F) acetate in hotspot 3 (PDB 4B9K).[10] In (B),
note the rearrangement of gate amino acid R120VHL. In (C)
and (D), amino acids of the symmetry-related protomer in the crystal
are labeled with * and colored bright orange. (E,F) Amino acids are
colored according to the percentage of frames in the mixed-solvent
MD simulation they are in contact with a buried probe, as in Figure . Hydrogen bonds
and salt bridges are shown as yellow dashed lines, and in (C) and
(D) they are colored red if they occur as part of a crystal contact.
Structural analysis of
VHL:EloC:EloB E3 ubiquitin ligase sites.
Surface representation of the cryptic pocket in VHL in (A) the VCBH:MB756
cocrystal structure (PDB 6GMR) and in (B) a frame extracted from the MD trajectory
of VCB cosolvated with dioxopiperazine. Cul site in EloC upon superposition
of VCB:Cul2 (PDB 4WQO),[39] shown fogged, with (C) VCBH (PDB 4AJY)[11] and with (D) Gustavus:EloCB (PDB 2FNJ).[47] Crystal structure of VCB with (E) glycerol in hotspot 1
(PDB 4AJY) and
(F) acetate in hotspot 3 (PDB 4B9K).[10] In (B),
note the rearrangement of gate amino acid R120VHL. In (C)
and (D), amino acids of the symmetry-related protomer in the crystal
are labeled with * and colored bright orange. (E,F) Amino acids are
colored according to the percentage of frames in the mixed-solvent
MD simulation they are in contact with a buried probe, as in Figure . Hydrogen bonds
and salt bridges are shown as yellow dashed lines, and in (C) and
(D) they are colored red if they occur as part of a crystal contact.Apart from detecting the three
ligandable sites in VCB, we were
also interested in locating pockets elsewhere in the protein surface.
SiteMap and FTMap proposed an additional, albeit low-druggable, site
in VHL (labeled as “hotspot 1” in Figure ). The same pocket was also identified by
mixed-solvent MD, as well as two unique sites in VHL and EloBC (“hotspot
2” and “hotspot 3″, respectively). We mined the
Protein Data Bank (PDB) for crystal structures of VHL, EloC, and EloB,
aiming at identifying intermolecular contacts and nonmodeled electron
density in hotspots 1–3. Additionally, we also inspected the
binding sites of MB235, MB756, and MB1200 for contacts that could
inform future structure-based fragment growing endeavors.We
gathered a total of 45 crystal structures: 36 crystal structures
of VCB and 9 crystal structures of complexes of EloBC with viral factors
or substrate-recognition subunits other than VHL (SI, Table S5). While we could not identify contacts
involving the MB756 cryptic pocket, crystal contacts were found in
the HIF-recognition site (SI, Figure S11) and the MB235/MB1200 pocket in EloC. In VCB:HIF-1α peptide
crystal structures, the EloC pocket is occupied by M568HIF-1α of a symmetry-related protomer (Figure C). In addition, the side chain of E64EloC, which assists in Cul2-recognition by VCB by hydrogen-bonding
to S40Cul2, engages in a hydrogen bond with the backbone
of I566HIF-1α. Similarly, in a crystal structure
of EloBC in complex with Gustavus (Gus), which is the substrate-recognition
subunit of the CRL5Gus E3 ubiquitin ligase, the same cavity
is occupied by L67Gus of a symmetry-related unit, whereas
E64EloC flips and interacts with R65Gus and
H82Gus (Figure D). Notably, side chain flexibility of E64EloC is
also observed in the presence of fragments MB235 and MB1200 (Figure A,B).We extended
the analysis to hotspots 1–3 predicted computationally
(Figure ). We found
a crystal structure of VCB with glycerol bound to hotspot 1, sandwiched
in a polar cleft and engaging in two hydrogen bonds with R161VHL (Figure E). In hotspot 2, we found crystal structures of VCB with an elongated
blob of nonmodeled electron density that did not match a water molecule,
suggesting that a small solvent molecule may be trapped in the cavity
(SI, Figure S12). We also found several
crystals of VCB in complex with HIF small-molecule mimetics with a
water molecule located in hotspot 3. In some cases, the water is displaced
by an acetate that satisfies hydrophobic contacts with Y18EloC, I30EloC, and I34EloB (Figure F).
Conclusions
In summary, we report
crystal structures of the VHL:EloC:EloB E3
ubiquitin ligase in complex with fragment-based screening hits. Two
fragments bound to a small cavity at the EloC:Cul interface, whereas
another fragment bound to a novel cryptic pocket in VHL. We also subject
the VCB complex to computational surface probing and study all binding
sites by systematic analysis of available crystal structures of VHL,
EloC, and EloB. We identify crystal contacts in the EloC pocket that
could inform future fragment elaboration as well as solvents bound
to potential hotspots proposed computationally. Additionally, we detect
formation of the VHL cryptic pocket during the MD simulations by rearrangement
of the gate amino acid R120VHL, as observed crystallographically.The discovered cryptic pocket in VHL involves R200VHL, which is highly mutated in Chuvash polycythemia, and P154VHL, which has been proposed to play an important role in substrate
poly ubiquitylation by CRLs.[45,46] The presented fragment-bound
structures of VCB will guide the development and optimization of more
potent ligands.[43] Binders of the cryptic
pocket could be optimized into an allosteric ligand or stabilizing
probe for the Chuvash mutant protein, whereas EloC binders could be
used to disrupt the assembly of CRL2 ligases[49] and to study the biology of EloC-containing E3 ligases. Additionally,
elaborated binders of the newly identified ligandable sites could
also be converted into targeted protein degraders. Indeed, the realization
that persistent and cooperative de novo protein–protein recognition,
rather than target binding affinity, dictates preferential substrate
degradation,[18] and that suboptimal VHL
ligands can render very potent degraders,[50] suggests that even weak binders of secondary pockets in E3 ligases
could be used as anchoring ligands for PROTAC conjugation.
Experimental Section
Tested compounds
were purchased and have a purity ≥95% (HPLC
analysis).
Authors: Caroline M Robb; Jacob I Contreras; Smit Kour; Margaret A Taylor; Mohammad Abid; Yogesh A Sonawane; Muhammad Zahid; Daryl J Murry; Amarnath Natarajan; Sandeep Rana Journal: Chem Commun (Camb) Date: 2017-07-04 Impact factor: 6.222
Authors: Dima Kozakov; David R Hall; Gwo-Yu Chuang; Regina Cencic; Ryan Brenke; Laurie E Grove; Dmitri Beglov; Jerry Pelletier; Adrian Whitty; Sandor Vajda Journal: Proc Natl Acad Sci U S A Date: 2011-08-01 Impact factor: 11.205
Authors: Jung-Hyun Min; Haifeng Yang; Mircea Ivan; Frank Gertler; William G Kaelin; Nikola P Pavletich Journal: Science Date: 2002-05-09 Impact factor: 47.728
Authors: Ryan C Russell; Roxana I Sufan; Bing Zhou; Pardeep Heir; Severa Bunda; Stephanie S Sybingco; Samantha N Greer; Olga Roche; Samuel A Heathcote; Vinca W K Chow; Lukasz M Boba; Terri D Richmond; Michele M Hickey; Dwayne L Barber; David A Cheresh; M Celeste Simon; Meredith S Irwin; William Y Kim; Michael Ohh Journal: Nat Med Date: 2011-06-19 Impact factor: 53.440
Authors: Haibin Zhou; Longchuan Bai; Renqi Xu; Yujun Zhao; Jianyong Chen; Donna McEachern; Krishnapriya Chinnaswamy; Bo Wen; Lipeng Dai; Praveen Kumar; Chao-Yie Yang; Zhaomin Liu; Mi Wang; Liu Liu; Jennifer L Meagher; Han Yi; Duxin Sun; Jeanne A Stuckey; Shaomeng Wang Journal: J Med Chem Date: 2019-12-10 Impact factor: 7.446